Mutant FTase with efficient transfructosylation activity

Mutant FTases from Aspergillus, engineered for high-purity expression in Pichia pastoris, address the inefficiencies of conventional fructooligosaccharide production by enhancing catalytic efficiency and reducing costs, achieving high yields and purity levels.

JP2024543124APending Publication Date: 2024-11-19REVELATIONS BIOTECH PVT LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024530524
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-22
Filing Date
2022-11-22
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing methods for producing fructooligosaccharides face limitations such as low catalytic efficiency, feedback inhibition, and high production costs due to enzyme stability and purification challenges, making it difficult to achieve large-scale, cost-effective production.

Method used

Development of mutant FTase enzymes from Aspergillus species through enzyme engineering and bioinformatics, optimized for expression in Pichia pastoris, which are fused with signal peptides and expressed using constitutive or inducible promoters, allowing high-purity enzyme production without costly chromatography steps.

Benefits of technology

The mutant FTases achieve high yields of fructooligosaccharides with improved catalytic efficiency and reduced production costs, achieving purity levels of 85% and concentrations of 2-5 grams/L.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543124000027
    Figure 2024543124000027
  • Figure 2024543124000028
    Figure 2024543124000028
  • Figure 2024543124000029
    Figure 2024543124000029
Patent Text Reader

Abstract

The present invention relates to improved microbial enzymes with transfructosylation activity for the efficient and cost-effective production of fructooligosaccharides. [Solution] The present invention is directed to obtaining mutant FTase gene family from the genus Aspergillus. Nucleic acids, peptide sequences, mutant proteins, vectors and host cells for recombinant expression of novel FTases are also provided. Various mutations, including but not limited to point mutations and deletion mutations and combinations thereof, are presented herein. The present invention also relates to a process of expression of novel recombinant FTase mutants as secreted proteins. The enzymes show high purity after filtration, which eliminates the need for costly chromatography procedures.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THEINVENTION The present invention relates to the field of genetic engineering directed to obtaining improved microbial enzymes with transfructosylation activity for efficient and cost-effective production of fructooligosaccharides. More specifically, the present invention is directed to obtaining mutant FTase gene family from Aspergillus. [Background technology]

[0002] background Fructose oligomers, also known as fructooligosaccharides (FOS), constitute a series of homologous oligosaccharides. Fructooligosaccharides are usually represented by the formula GF n and is composed mainly of 1-kestose (GF2), nystose (GF3) and β-fructofuranosylnystose (GF4), in which 2, 3 and 4 fructosyl units are linked at the β-2,1 positions of glucose.

[0003] Fructooligosaccharides (FOS) are characterized by many beneficial properties, such as low sweetness intensity and usefulness as a prebiotic. Due to their low sweetness intensity (approximately one-third to two-thirds compared to sucrose) and low calorific value (approximately 0-3 kcal / g), fructooligosaccharides can be used as sugar substitutes in various foods. Furthermore, as a prebiotic, fructooligosaccharides have been reported for use as protective agents against colon cancer, enhancing various parameters of the immune system, improving mineral adsorption, beneficial effects on serum lipid and cholesterol concentrations, and glycemic control for the management of obesity and diabetes (Dominguez, Ana Luisa, et al. “An overview of the recent developments on fructooligosaccharide production and applications.” Food and bioprocess technology 7.2 (2014): 324-337).

[0004] However, fructooligosaccharides are only found in trace amounts as natural constituents in fruits, vegetables and honey. Due to such low concentrations, it is virtually impossible to extract fructooligosaccharides from food.

[0005] Attempts have been made to produce fructooligosaccharides through enzymatic synthesis from sucrose by microbial enzymes with transfructosylating activity. However, the main limitations of previous attempts have been the feedback inhibition of the enzymes by glucose, which results in lower catalytic efficiency, lower FOS yield, and longer conditions for the conversion of sucrose by the enzymes expressed in recombinant host systems. Furthermore, industrial production of microbial enzymes exhibiting transfructosylating activity is difficult due to additional limitations associated with large-scale expression of the enzymes, enzyme stability, fermentation and purification processes.

[0006] Commercial-scale production of fructooligosaccharides requires the identification and mass production of efficient enzymes. Due to the above limitations, the production of microbial enzymes with efficient transfructosylation activity is therefore a costly endeavor that increases the production cost of fructooligosaccharides.

[0007] Therefore, there is a long-standing and continuing need to identify and provide efficient, inexpensive and industrially useful enzymes with good transfructosylation activity, which in turn will reduce the cost of production of fructooligosaccharides.

[0008] The FTase gene / protein family includes several enzymes, such as, but not limited to, β-fructofuranosidase from Aspergillus niger, fructosyltransferase from Aspergillus japonicus, arabinanase / levansucrase / invertase from Aspergillus fijiensis, and fructosyltransferase from Aspergillus aculeatus. The amino acid sequences of these proteins are represented by SEQ ID NOs: 1, 2, 3, and 4). These enzymes exhibit transfructosylation activity and are therefore important in the production of fructo-oligosaccharides.

[0009] Although β-fructofuranosidase and fructosyltransferase have been produced from Aspergillus, there is still a need for efficient and cost-effective enzymes. The present invention attempts to address the above problems in the prior art by generating various mutants and various strains that allow better enzymes to be obtained in good quantities. Summary of the Invention [Problem to be solved by the invention]

[0010] Summary of the Invention technical challenges The technical problem to be solved by the present invention is to provide a novel enzyme having excellent transfructosylation activity. [Means for solving the problem]

[0011] Solutions to the problems The problem was solved by using a unique enzyme engineering and bioinformatics-based approach to develop mutants of FTase from Aspergillus.

[0012] Summary of the Invention The present invention relates to nucleic acids, peptide sequences, mutant proteins, vectors and host cells for the recombinant expression of novel FTases, including but not limited to β-fructofuranosidase or fructosyltransferase enzymes. Various mutants, including but not limited to point mutants and deletion mutants and combinations thereof, are presented herein. The present invention also relates to a process for the expression of novel recombinant FTase mutants as secreted proteins. The enzymes show high purity after filtration, which eliminates the need for costly chromatography procedures.

[0013] Finally, enzymes can be used to obtain high yields of fructooligosaccharides.

[0014] BRIEF DESCRIPTION OF THE DRAWINGS Features of the present disclosure will become more apparent from the following detailed description taken in conjunction with the accompanying drawings, in which: The present disclosure is further described through the use of the accompanying drawings, with the understanding that the drawings merely illustrate some embodiments according to the present disclosure and should not be considered as limiting its scope. [Brief description of the drawings]

[0015] [Figure 1] A multiple sequence alignment of native FTases from several representative Aspergillus species is shown. [Figure 2a-1] 1 shows a multiple sequence alignment of the native and modified fopA genes. [Figure 2a-2] 1 shows a multiple sequence alignment of the native and modified fopA genes. [Figure 2b-1] 1 shows a multiple sequence alignment of the native and modified ft genes. [Figure 2b-2] 1 shows a multiple sequence alignment of the native and modified ft genes. [Diagram 3] 1 shows a construction scheme of the pPICZαA vector. [Figure 4-1]1 shows the results of restriction digestion analysis performed on recombinant plasmid pPICZαA, which contains: (a): V44L; (b): T155R; (c): T293W and R286V. [Figure 4-2] 1 shows the results of restriction digestion analysis performed on recombinant plasmid pPICZαA containing: (d): T459R; (e): R199K; (f): F182P; (g): 32-654aa, 32-194aa, and 1-194aa mutants. [Figure 5-1] Figure 2 SDS-PAGE analysis for screening protein expression in Pichia pastoris recombinant strains harboring integration (a): pPICZαA-V44L; (b): pPICZαA-T155R. [Figure 5-2] Figure 2 shows SDS-PAGE analysis for screening protein expression in Pichia pastoris recombinant strains harboring the integration (c): pPICZαA-T293W; (d): pPICZαA-R286V. [Figure 5-3] Figure 2 shows SDS-PAGE analysis for screening protein expression in Pichia pastoris recombinant strains harboring the integration (e): pPICZαA-R199K; (f): pPICZαA-T459R. [Figure 5-4] Integration (g): SDS-PAGE analysis for screening protein expression in Pichia pastoris recombinant strains harboring pPICZαA-F182P. [Figure 6-1] SDS-PAGE analysis of samples collected at different time intervals during the fermentation chase of various mutant FTase proteins: (a): pPICZαA-V44L; (b): pPICZαA-T155R. [Figure 6-2] SDS-PAGE analysis of samples collected at different time intervals during the fermentation chase of various mutant FTase proteins: (c): pPICZαA-T293W; (d): pPICZαA-R286V. [Figure 6-3] SDS-PAGE analysis of samples collected at different time intervals during the fermentation chase of various mutant FTase proteins: (e): pPICZαA-R199K; (f): pPICZαA-T459R; (g): pPICZαA-F182P. [Figure 7-1] TLC showing the formation of FOS from sucrose by mutant enzymes: (a): V44L; (b): T155R. [Figure 7-2] TLC showing the formation of FOS from sucrose by mutant enzymes: (c): T293W; (d): R286V. [Figure 7-3] TLC showing the formation of FOS from sucrose by mutant enzymes: (e): R199K; (f): T459R; (g): F182P. [Figure 8-1] HPLC analysis chromatographs of FOS samples formed by mutant enzymes: (a): V44L; (b): T155R. [Figure 8-2] HPLC analysis chromatographs of FOS samples formed by mutant enzymes: (c): T293W; (d): R286V. [Figure 8-3] HPLC analysis chromatographs of FOS samples formed by mutant enzymes: (e): R199K; (f): T459R. [Figure 8-4] HPLC analysis chromatographs of FOS samples formed by mutant enzymes (g): F182P. [Figure 9-1] 1 shows the results of restriction digestion analysis performed on recombinant plasmid pPICZαA containing (a): N32R, H43Y, H43V, H43L, V125F, V127A, P131Y; (b): F182R, F182A, F182D, F182V, F182T, T293F, T293H. [Figure 9-2] Shown are the results of restriction digestion analysis performed on recombinant plasmid pPICZαA containing (c): T293R, T293L, T293S, Q327L; (d): Q327N, V343F. [Figure 10-1] Figure 1 SDS-PAGE analysis for screening protein expression in Pichia pastoris recombinant strains harboring integration (a): pPICZαA-H43Y; (b): pPICZαA-H43L. [Figure 10-2] Figure 2 shows SDS-PAGE analysis for screening protein expression in Pichia pastoris recombinant strains harboring the integration (c): pPICZαA-Q327N; (d): pPICZαA-V343F. [Figure 11] FIG. 1 shows a workflow for identifying stabilizing point mutations in FTase. [Figure 12] 1 shows the comparative sequences of the ft and fopA genes. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] BRIEF DESCRIPTION OF THE SEQUENCES AND SEQUENCE LISTING

[0017] [Table 1]

[0018] [Table 2]

[0019] [Table 3]

[0020] [Table 4]

[0021] [Table 5]

[0022] [Table 6]

[0023] [Table 7]

[0024] [Table 8]

[0025] [Table 9]

[0026] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the method belongs. Although any vectors, host cells, methods and compositions similar or equivalent to those described herein can also be used in the practice or testing of vectors, host cells, methods and compositions, a representative description is provided here.

[0027] When a range of values ​​is provided, it is understood that each intervening value between the upper and lower limits of that range, as well as any other stated or intervening value in that stated range, is encompassed in the methods and compositions. The upper and lower limits of these smaller ranges may be independently included in the smaller ranges, and each such range is also encompassed in the methods and compositions, subject to any specifically excluded limits in the stated range. When the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the methods and compositions.

[0028] It is recognized that, for clarity, certain features of the method described in the context of separate embodiments may also be provided in combination with a single embodiment. Conversely, for brevity, various features of the method and compositions described in the context of a single embodiment may also be provided separately or in any suitable subcombination. It is noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. Thus, this statement is intended to serve as a predicate for the use of exclusive terminology such as "solely," "only," and the like in relation to the recitation of claim elements or the use of a "negative" limitation.

[0029] As will be apparent to one of ordinary skill in the art upon reading this disclosure, each of the individual embodiments depicted and illustrated herein has distinct components and features which may be readily separated from or combined with the features of any of the other embodiments without departing from the scope or spirit of the method. Any recited method may be carried out in the order of events recited or in any other order which is logically possible.

[0030] The term "host cell" includes an individual cell or cell culture that can be or has been a recipient for the subject of an expression construct. A host cell includes the progeny of a single host cell. A host cell for the purposes of the present invention refers to any strain of Pichia pastoris that can be suitably used for the purposes of the present invention. Examples of strains that can be used for the purposes of the present invention include wild type, mut+, mutS, mut- strains of Pichia, such as KM71H, KM71, SMD1168H, SMD1168, GS115, X33.

[0031] The term "recombinant strain" or "recombinant host cell" refers to a host cell transfected or transformed with an expression construct or vector of the present invention.

[0032] The term "expression vector" refers to any vector, plasmid or vehicle designed to enable the expression of an inserted nucleic acid sequence following transformation into a host.

[0033] The term "promoter" refers to a DNA sequence that defines where transcription of a gene begins. Promoter sequences are typically located directly upstream or at the 5' end of the transcription start site. RNA polymerase and necessary transcription factors bind to the promoter sequence and initiate transcription. Promoters can be either constitutive or inducible. Constitutive promoters are promoters that allow for continuous transcription of their associated gene, since the expression of the associated gene is usually not conditional by environmental and developmental factors. Constitutive promoters are extremely useful tools in genetic engineering because they drive gene expression under conditions without inducers and often exhibit better characteristics than commonly used inducible promoters. Inducible promoters are promoters that are induced by the presence or absence of biotic or non-biotic and chemical or physical factors. Inducible promoters are extremely powerful tools in genetic engineering because the expression of genes operably linked to them can be switched on or off at certain stages of development or growth of an organism or in a particular tissue or cell type.

[0034] The term "operably linked" refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is regulated by the other. For example, a promoter is operably linked with a coding sequence if it is capable of regulating the expression of that coding sequence (i.e., that coding sequence is under the transcriptional control of the promoter).

[0035] The term "transcription" refers to the process of making an RNA copy of a gene sequence. This copy, called a messenger RNA (mRNA) molecule, leaves the cell nucleus and enters the cytoplasm, where it directs the synthesis of the protein it codes for.

[0036] The term "translation" refers to the process of translating the sequence of a messenger RNA (mRNA) molecule into a sequence of amino acids during protein synthesis. The genetic code describes the relationship between the sequence of base pairs in a gene and the corresponding amino acid sequence it codes for. In the cytoplasm, ribosomes read the sequence of mRNA in groups of three to assemble proteins.

[0037] The term "expression" refers to the biological production of a product encoded by a coding sequence. In most cases, a DNA sequence, including a coding sequence, is transcribed to form a messenger RNA (mRNA). The messenger RNA is then translated to form a polypeptide product having the relevant biological activity. The process of expression may also include further processing steps on the RNA product of transcription, such as splicing to remove introns and / or post-translational processing of the polypeptide product.

[0038] As used herein, the term "modified polypeptide / polynucleotide" is used to refer to a polypeptide FTase selected from, but not limited to, a β-fructofuranosidase and / or fructosyltransferase mutant fused to a signal peptide or a polynucleotide encoding the same. Functional variants include any nucleic acid that has significant or significant sequence identity or similarity with the β-fructofuranosidase and / or fructosyltransferase mutants described herein and retains their biological activity.

[0039] The term "variant" as used herein with respect to precursor peptides / proteins refers to peptides having amino acid substitutions, additions, deletions or alterations that do not substantially reduce the activity of the signal peptide or enzyme. Variants include structural and functional variants. The term variant also includes the use of substituted amino acids in place of unsubstituted parent amino acids.

[0040] Amino acid substitution tables providing functionally similar amino acids are well known to those of skill in the art. The following six groups (Table 1) are examples of amino acids that are considered variants of one another:

[0041] [Table 10]

[0042] The term "point mutation" refers to a large category of mutations that represent a change in a single nucleotide of DNA such that the nucleotide is exchanged for another nucleotide, or a nucleotide is deleted or a single nucleotide is inserted into the DNA, thereby causing the DNA to differ from the normal or wild-type gene sequence.

[0043] The term "deletion mutation" refers to a type of mutation that involves the loss of genetic material. This can be small, involving a single missing DNA base pair, or large, involving part of a chromosome.

[0044] The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to two or more amino acid residues linked together by peptide bonds or modified peptide bonds. The term applies to amino acid polymers in which one or more amino acid residues are artificial chemical mimics of the corresponding naturally occurring amino acid, as well as naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymers. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and longer chains, commonly referred to as proteins. Polypeptides can contain amino acids other than the 20 genetically encoded amino acids. Similarly, "protein" refers to at least two covalently linked amino acids, including proteins, polypeptides, oligopeptides, and peptides. Proteins can be composed of naturally occurring amino acids and peptide bonds or synthetic peptidomimetic structures. Thus, "amino acid" or "peptide residue" as used herein refers to both naturally occurring and synthetic amino acids. "Amino acid" includes imino acid residues, such as proline and hydroxyproline. The side chains can be in either the (R) or (S) configuration.

[0045] The term "signal peptide" or "signal peptide sequence" is defined herein as a peptide sequence usually present at the N-terminus of newly synthesized secretory or membrane polypeptides that directs the polypeptide across or into the cell membrane (plasma membrane in prokaryotes and endoplasmic reticulum membrane in eukaryotes) of a cell. It is usually subsequently removed. In particular, said signal peptide may be capable of directing the polypeptide into the secretory pathway of a cell.

[0046] The term "precursor peptide" as used herein refers to a peptide that includes a signal peptide (also known as a leader sequence) operably linked to the respective FTase from Aspergillus. The signal peptide is cleaved off during post-translational modification inside the Pichia host cell and the mature FTase mutant is released into the medium.

[0047] Detailed Description of the Invention The present invention is described by the following specific embodiments. Those skilled in the art can easily understand other advantages and features of the present invention after reading the disclosure of this specification. Various details described in this specification can be modified based on different conditions and applications without departing from the scope of the present invention disclosed herein.

[0048] Throughout this specification, the terms "a" and "an" mean one or more, and the term "or" means and / or, unless contraindicated or specifically stated.

[0049] The use of "comprise," "comprises," "including," "contain," "contains," "containing," "include," "includes," and "comprising" is not intended to be limiting. It is to be understood that both the foregoing general description and this detailed description are exemplary and explanatory only and are not restrictive.

[0050] As used herein, biotechnology terms have their customary meaning as explained by the following explanatory definitions.

[0051] Unless otherwise defined, scientific and technical terms used herein shall have the meanings commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include the plural and plural terms shall include the singular.

[0052] The foregoing has outlined broadly the features and technical advantages of the present disclosure in order that the detailed description of the disclosure that follows may be better understood. It should be appreciated by those skilled in the art that the concept and specific embodiments disclosed may be readily utilized as a basis for modifying the disclosed methods or for carrying out the same purposes of the present disclosure.

[0053] Fructosyltransferase (FT) enzymes are members of the glucose hydrolase 32 family (GH32) that catalyze the production of fructose oligosaccharides, fructans, through a retention mechanism. The three-dimensional structure of the enzyme FT (AjFT) from Aspergillus japonicus has been solved, providing a structural basis for the substrate binding and catalysis performed by this enzyme. Among the structures solved by Chuankhayan et. al.[1], the apo structure (PDB ID: 3LF7) and the kestose-bound (PDB ID: 3LDR) structure of AjFT are relevant to this study.

[0054] The present invention discloses nucleic acids, vectors and recombinant host cells for efficient production of biologically active and soluble recombinant FTases, including, but not limited to, β-fructofuranosidase from Aspergillus niger, fructosyltransferase from Aspergillus japonicus, arabinanase / levansucrase / invertase from Aspergillus fijiensis, fructosyltransferase from Aspergillus aculeatus, and mutants thereof obtained from Aspergillus, as secreted proteins. Further, the present invention provides a process for commercial-scale production of recombinant β-fructofuranosidase and / or fructosyltransferase mutants. As representative but not limiting examples, we mention the fructosyltransferase encoded by the ft gene of Aspergillus japonicus and the β-fructofuranosidase encoded by the fopA gene of Aspergillus niger.

[0055] The present invention contemplates a multi-dimensional approach to achieve high yields of novel recombinant FTase mutants in heterologous hosts. Codon-optimized genes for FTases selected from, but not limited to, fructosyltransferase or β-fructofuranosidase, arabinanase / levansucrase / invertase are modified by mutation for expression in Pichia pastoris. The mutations can be point mutations or deletion mutations or combinations thereof.

[0056] In one embodiment, the codon-optimized genes for β-fructofuranosidase and / or fructosyltransferase are modified for expression in a heterologous host cell, and the modified genes are fused to one or more signal peptides.

[0057] In one embodiment, the codon-optimized nucleic acid encoding an Aspergillus niger β-fructofuranosidase is represented by SEQ ID NO:6.

[0058] In one embodiment, the codon-optimized nucleic acid encoding the engineered fructosyltransferase of Aspergillus japonicus is represented by SEQ ID NO:8.

[0059] In another embodiment, the modified nucleic acid is fused to one or more signal peptides.

[0060] In another embodiment, the signal peptide is selected from the group consisting of alpha factor (FAK) from S. cerevisiae, alpha factor full length (FAKS) from S. cerevisiae, alpha factor_T (AT) from S. cerevisiae, alpha-amylase (AA) from Aspergillus niger, glucoamylase (GA) from Aspergillus awamori, inulinase (IN) from Kluyveromyces maxianus, invertase (IV) from S. cerevisiae, killer protein (KP) from S. cerevisiae, Gallus gallus, and the like. gallus lysozyme (LZ), and Homo sapiens serum albumin (SA).

[0061] In another embodiment, the signal peptide is provided in Table 2.

[0062] [Table 11]

[0063] In another embodiment, the recovered β-fructofuranosidase from Aspergillus niger and fructosyltransferase from Aspergillus japonicus were characterized to identify bioactive fragments. The following bioactive fragments of the conserved FTase were found to be responsible for catalytic activity and are provided in Table 3 below.

[0064] [Table 12]

[0065] In another embodiment, in all secretory signal peptide sequences, a stretch of four amino acids (LEKR) was added for efficient Kex2 processing of the preproteins provided in Table 4.

[0066] [Table 13]

[0067] [Table 14]

[0068] In another embodiment, the modified nucleic acid is cloned into an expression vector.

[0069] In another embodiment, the expression vector is configured for secretion or intracellular expression of recombinant FTase from Aspergillus.

[0070] In yet another embodiment, the expression vector is selected from the group including pPICZαA, pPICZαB, pPICZαC, pGAPZαA, pGAPZαB, pGAPZαC, pPIC3, pPIC3.5, pPIC3.5K, PAO815, pPIC9, pPIC9K, pHIL-D2 and pHIL-S1.

[0071] In another embodiment, expression of the modified FTase gene fused to a signal peptide is preferably driven by a constitutive or inducible promoter.

[0072] In another embodiment, the nucleic acid to be expressed is operably linked to a promoter.

[0073] In another embodiment, the constitutive or inducible promoter is selected from the group listed in Table 5 below.

[0074] [Table 15]

[0075] In another embodiment, the promoter is the AOX1 promoter, which is induced by methanol and repressed by glucose.

[0076] In one embodiment, an expression vector containing the modified gene of interest (the FTase gene fused to a nucleic acid encoding a signal peptide) is transformed into a suitable host.

[0077] In one embodiment, there is provided a method for producing a recombinant host cell capable of expressing an engineered FTase of Aspergillus sp., comprising the steps of: a. synthesizing a modified nucleic acid molecule from an Aspergillus sp. as defined in claim 6; b. constructing a vector carrying the modified nucleic acid molecule; c. transforming a host cell with the vector of step (b) to obtain a recombinant host cell; The method includes:

[0078] In one embodiment, the codon-optimized genes for β-fructofuranosidase and / or fructosyltransferase are engineered for expression in a heterologous host cell.

[0079] In one embodiment, the heterologous recombinant host cell is a prokaryotic host selected from the group including Escherichia coli, Bacillus subtilis, Pseudomonas putida, Corynebacterium glutamicum, and the like.

[0080] In another embodiment, the heterologous recombinant host cell is a eukaryotic host cell, which may be selected from the group including Saccharomyces cerevisiae, Pichia pastoris, and Hansenula polymorpha.

[0081] In another embodiment, an expression vector containing the gene of interest is transformed into yeast cells.

[0082] In another embodiment, the yeast cell is Pichia pastoris.

[0083] In yet another embodiment, the Pichia Pastoris host cell is a mut+, mutS or mut- strain, where Mut+ denotes a positive phenotype for methanol utilization.

[0084] In yet another embodiment, the Pichia Pastoris host cell strain is selected from the group comprising KM71H, KM71, SMD1168H, SMD1168, GS115, X33.

[0085] In another embodiment, the present invention provides a FTase precursor peptide, in which an Aspergillus FTase is fused to one or more signal peptides.

[0086] In an important embodiment, Aspergillus FTase mutants and processes for producing mutants are provided. The mutations can be single, double or triple point mutations and deletion mutants, and also combinations of these mutations.

[0087] In another embodiment, there is provided a nucleic acid sequence of an engineered β-fructofuranosidase from Aspergillus niger as set forth in SEQ ID NOs: 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65.

[0088] In another embodiment, there is provided a peptide sequence of an engineered β-fructofuranosidase from Aspergillus niger as set forth in SEQ ID NOs: 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 67-218.

[0089] In another embodiment, the signal peptide is selected from the group consisting of S. cerevisiae alpha factor full length (FAK) as set forth in SEQ ID NO: 219, S. cerevisiae alpha factor full length (FAKS) as set forth in SEQ ID NO: 229, S. cerevisiae alpha factor_T (AT) as set forth in SEQ ID NO: 220, Aspergillus niger alpha-amylase (AA) as set forth in SEQ ID NO: 221, Aspergillus awamori glucoamylase (GA) as set forth in SEQ ID NO: 222, Kluyveromyces maxianus inulinase (IN) as set forth in SEQ ID NO: 223, S. cerevisiae alpha factor full length (FAK) as set forth in SEQ ID NO: 224, S. cerevisiae invertase (IV), S. cerevisiae killer protein (KP) as set forth in SEQ ID NO: 225, Gallus gallus lysozyme (LZ) as set forth in SEQ ID NO: 226, Homo sapiens serum albumin (SA) as set forth in SEQ ID NO: 227, and variants thereof.

[0090] In yet another embodiment, the mutants were generated by conventional genetic engineering techniques and by utilizing bioinformatics-based tools. Point mutations were predicted and introduced into the codon-optimized β-fructofuranosidase (fopA) gene of Aspergillus niger and / or the ft gene of Aspergillus japonicus. Conventional genetic engineering, such as PCR, bioinformatics tools utilizing molecular dynamics simulation using the software GROMACS, and approaches such as the introduction of codon bias were used in the present invention.

[0091] In one embodiment, a fructosyltransferase mutant is provided as set out below. Point Mutants: V44L, T155R, T293W, R286V, T459R, R199K, F182P Deletion mutants: 32~654aa, 32~194aa, 1~194aa

[0092] In one embodiment, a process for the production of recombinant FTase from Aspergillus is provided.

[0093] An embodiment of the present invention relates to the fermentation of recombinant Pichia pastoris cells containing an engineered / mutated recombinant FTase gene. After completion of the fermentation, the fermentation broth is subjected to centrifugation and filtered using microfiltration to separate the recombinant enzyme. The recovered recombinant enzyme is concentrated using tangential flow ultrafiltration or evaporation, and finally the concentrated enzyme is formulated.

[0094] In one embodiment, a process for expressing an engineered FTase from Aspergillus sp. is provided, comprising: a. culturing a recombinant host cell capable of expressing an Aspergillus sp. FTase in a suitable fermentation medium to obtain a fermentation broth; b. recovering a supernatant from the fermentation broth, the supernatant containing the recombinant FTase; c. Purifying the recombinant FTase; The process includes:

[0095] In another embodiment, the fermentation medium is a basal salts medium as set forth in Table 6 below.

[0096] [Table 16]

[0097] In yet another embodiment, the supernatant from the fermentation broth is collected using centrifugation.

[0098] In one embodiment, the inoculum or starter culture rate for initiating the fermentor culture ranges from 2.0% to 15.0% (v / v).

[0099] In another embodiment, the pH of the fermentation medium is maintained in the range of 4.0 to 7.5, since the secreted enzymes undergo proper folding and are biologically active in this pH range.

[0100] In yet another embodiment, the temperature of the fermentation process ranges from 15°C to 40°C.

[0101] In another embodiment, the time for the fermentation process ranges from 50 to 150 hours.

[0102] In a further embodiment, the fermentation broth is centrifuged at speeds ranging from 2000×g to 15000×g using continuous online centrifugation.

[0103] The supernatant obtained after centrifugation is subjected to microfiltration to purify and recover the biologically active recombinant / mutant FTase.

[0104] In one embodiment, the supernatant obtained after centrifugation is concentrated using a tangential flow filtration-based ultrafiltration system.

[0105] The cut-off size of membranes used in tangential flow filtration (TFF) systems, which can be used to remove impurities and concentrate harvested culture supernatants, can range from 5 to 100 kDa.

[0106] In another embodiment, centrifugation is not required for the process due to the high yield and purity of the secreted enzyme.

[0107] The FTase concentration obtained in the present invention is found to be in the range of 2 to 5 g / L or more, and has a high purity of about 85% or more.

[0108] In one embodiment, a process for identifying amino acid mutations across the FTase protein chain that includes the active site, comprising the steps: a. Using bioinformatics tools to simulate the apo structure of the FTase enzyme; b. Clustering the trajectories based on the variation of root mean square deviation (RMSD) to identify unique conformations; c. Identifying the unique conformation that the FTase enzyme adopted during the course of the simulation residues for mutation; d. analyzing the unique conformations identified in step (c) for pairwise interactions of each amino acid with other amino acids; e. Quantifying pairwise interactions of amino acids as index interaction strengths by providing appropriate weights for van der Waals and hydrogen bonds between pairs of residues; f. generating 19 mutations of each amino acid found to have a larger standard deviation of interaction strengths through the course of the simulation; g. Identifying and selecting stabilizing mutations with similar or better stability according to -ΔΔG values; It is a process that includes: EXAMPLES

[0109] Working Example The following examples specifically describe the manner in which the invention may be practiced, but the embodiments disclosed herein in no way limit the scope of the invention.

[0110] Example 1: Engineered Nucleic Acids for Expression of Recombinant β-Fructofuranosidase of Aspergillus niger in Pichia pastoris The native cDNA of β-fructofuranosidase (SEQ ID NO: 5) was codon-optimized for maximum expression in Pichia pastoris. The codon-optimized nucleotide sequence of β-fructofuranosidase represented by (SEQ ID NO: 6) was further modified by introducing one or more point mutations defined in Table 7 or deletion mutations defined in Table 8 or combinations thereof, which were introduced into the codon-optimized nucleotide sequence. The amino acid and nucleotide sequences of the modified β-fructofuranosidase are represented by SEQ ID NOs: 9-218.

[0111] [Table 17]

[0112] [Table 18]

[0113] An expression cassette encoding β-fructofuranosidase was modified for maximal expression in Pichia pastoris. The modified open reading frame contains a modified nucleotide sequence encoding β-fructofuranosidase fused to a signal peptide. The nucleic acid was designed such that the encoded signal peptide contains an additional stretch of four amino acids (LEKR) for efficient Kex2 processing of the precursor peptide.

[0114] Preferred codons for expression in Pichia pastoris were used instead of rare codons. The nucleotide sequence of the modified open reading frame encoding β-fructofuranosidase was fused to a modified signal peptide. The recombinant precursor protein was obtained by translating the gene encoding β-fructofuranosidase from Aspergillus niger fused to the signal peptide. The signal peptide was cleaved off during post-translational modification inside the Pichia host cell, releasing the mature recombinant β-fructofuranosidase into the medium.

[0115] Example 2: Mutant Development Example 2(a): Bioinformatics approach: We sought to identify amino acid mutations along the protein chain including the active site that could result in greater stabilization of the protein AnFT, the enzyme FT from Aspergillus niger. To identify such amino acids, the apo structure of AnFT was subjected to a 25 ns molecular dynamics simulation using the software GROMACS.

[0116] Following the simulation, the trajectories were clustered based on the root mean square deviation (RMSD) variation of the CA atoms to identify unique conformations that the protein adopted during the course of the simulation. A representative structure of the cluster (cluster center) was selected.

[0117] These structures were analyzed for the interactions that each amino acid had with other amino acids. Pairwise interactions of amino acids were quantified as index interaction strengths by providing appropriate weights for van der Waals and hydrogen bonds between residue pairs. The strength of the interaction between amino acids i and j, Sij=Wt / rij where Wt is the weight for a given interaction type and rij is the distance between the atoms of residues i and j. The strength of an interaction calculated between two residues is the algebraic sum of the strengths of interactions between the atoms of the two residues.

[0118] This gives an NxN matrix for a protein of N residues, where each element represents an interaction strength, with 0 representing no interaction. The sum of each row in the matrix simply gives the overall interaction strength for a given amino acid. For example, total interaction strength of residue 100 = sum(interaction strengths of residue 100 with all other residues)

[0119] A radius of 5 Å was chosen as cutoff to analyze and quantify the interactions. No interactions were assumed between consecutive amino acids so that the interaction strength would accurately reflect the stabilization via tertiary structure. A greater interaction strength means a greater stabilization of the amino acid and therefore the protein.

[0120] The ensemble of AnFT structures that emerged from the molecular dynamics simulations and subsequent clustering consisted of 5–6 distinct conformations (cluster centers). For each of the conformations, an interaction strength matrix was generated and the individual interaction strengths of each amino acid were calculated as described above.

[0121] The variation of interaction strength of each amino acid across the ensemble was examined using the statistical parameter of standard deviation. A larger standard deviation of the interactions between the various conformations indicated flexible residues, while a lower standard deviation indicated well-networked residues. Mutants were generated by targeting flexible residues. An overview of the scheme for identification of the most stable sites for mutation is outlined in FIG. 11.

[0122] Furthermore, each such amino acid that was found to have a larger standard deviation in interaction strength over the course of the simulation was mutated to all other 19 natural amino acids that occur in proteins.

[0123] Furthermore, energies of stabilization were calculated for the mutated amino acids relative to the wild type and they were represented by the parameter ΔΔG, which indicates the difference between ΔG for the wild type and the stabilizing mutants. This analysis was carried out using the commercial software ICM from MolSoft. The ΔΔG (kcal / mol) values ​​for the mutations of each amino acid to 19 other amino acids were calculated and mutations that showed no further stabilization or showed better stabilization were selected. The list of mutations thus selected is given below in Table 9 together with the ΔΔG (kcal / mol) values ​​for each mutation.

[0124] [Table 19]

[0125] Similar exercises as above were performed on the kestose-bound AnFT structure to analyze the strength of amino acid interactions in the kestose-binding site and the effect of their mutations on protein stability, the results of which are shown in Table 10 below.

[0126] [Table 20]

[0127] As described above, at least 172 sites for point mutations were identified using a combination of molecular dynamics simulations, trajectory analysis, characterization of mutants for their individual amino acid interaction strengths and their stabilizing effect on the protein. Additionally, suitable sites for deletions were also identified based on prior art structural studies of the apo structure of FTase.

[0128] Example 2(b): Genetic Engineering Approach: Based on bioinformatics approach, alternative forms of functional domains for FTase protein were conceived and cloned to further test their validity for the process. For the cloning work, primers were designed to PCR amplify specific stretches of DNA from recombinant plasmids used as templates with codon-optimized full-length FTase gene. Thus, the amplified PCR products contained the required deletions and retained the desired stretches from the gene. These PCR products were cloned in the respective expression vectors in a compatible manner, for example as XhoI and SacII fragments in the corresponding sites in the MCS of vector pPICZαA.

[0129] Point mutations were introduced into the sequence of the FTase gene via primers carrying mutant nucleotides. The PCR products generated via these primers contained the mutant sequences at the corresponding sites. These PCR products now carrying the point mutations were then cloned into the desired expression vector according to the appropriate guidelines.

[0130] Example 3: Development of recombinant host cells by transformation with recombinant plasmids The vector used in this process was pPICZαA. The vector contained a modified open reading frame and an inducible promoter AOX1. The modified sequence encoding the recombinant protein was cloned into the pPICZαA vector.

[0131] The modified nucleic acids encoding the respective FTase genes were cloned using routine molecular biology procedures between the XhoI / SacII restriction sites present in the MCS of the pPICZαA vector to generate expression cassettes in frame with the signal sequence alpha factor of S. cerevisiae (FAK). The vector map for pPICZαA is presented in Figure 3.

[0132] Putative recombinant plasmids were selected on low-salt LB medium containing 25 μg / ml Zeocin and screened by XhoI / SacII restriction digestion analysis.

[0133] The recombinant plasmid pPICZαA-FTase was confirmed by XhoI / SacII restriction digestion analysis, which resulted in the release of a 1980 bp fragment. The results of the restriction digestion analysis are shown in FIG.

[0134] FIG. 9 shows the results of restriction digestion analysis performed on recombinant plasmid pPICZαA containing: (a): N32R, H43Y, H43V, H43L, V125F, V127A, P131Y; (b): F182R, F182A, F182D, F182V, F182T, T293F, T293H; (c): T293R, T293L, T293S, Q327L; (d): Q327N, V343F.

[0135] Pichia pastoris cells were then electroporated with the linearized recombinant pPICZαA-FTase DNA. Pichia integrants were selected on yeast extract peptone dextrose sorbitol agar (YPDSA) containing 100 μg / ml Zeocin.

[0136] Integration was screened by colony PCR (cPCR). For cPCR, templates from each of the Pichia integrants were generated by the alkaline lysis method.

[0137] Pichia integrants were grown for 48 hours in BMD1 medium and then induced first in BMM2 medium and then successively in BMM10 medium, which provided a final concentration of 0.5% methanol in the culture medium. At the end of the 96-hour induction period, culture supernatants from the different clones were harvested. Total proteins from each of the harvested supernatants were precipitated with 20% TCA and analyzed on SDS-PAGE.

[0138] Upon induction of the FTase protein, a band was observed at a size of approximately 110 kDa, as shown in FIG.

[0139] The calculated molecular weight was approximately 70.85 kDa. The increase in molecular weight could be due to glycosylation.

[0140] Example 4: Fermentation of recombinant Pichia pastoris expressing mutant FTase of Aspergillus Fermentation of recombinant Pichia pastoris cells containing the engineered FTase gene described in Example 1 was carried out in a 50 L fermentor. Fermentation was carried out in the basal salts medium described herein.

[0141] Preparation of pre-seed and seed inoculum: Preseed was generated by inoculating 25 mL of sterile YEPG medium from a glycerol stock and growing overnight at 30° C. in a temperature-controlled orbital shaker. To generate seed, the inoculum was grown in baffled shake flasks in basal salts medium at 30° C. in a temperature-controlled orbital shaker to an OD of 15-25. 600 was allowed to grow until it reached

[0142] Fermentation Process The entire fermentation process, from inoculation of the fermentor with the seed culture to final harvest, took approximately 130 hours. Basal salts medium was prepared and sterilized in situ in the fermentor.

[0143] The composition of the basal salts medium optimized for the fermentation process is provided in Table 6.

[0144] Pichia trace mineral (PTM) salts solution was prepared using the components listed in Table 11. The PTM salts were dissolved, made up to 1 L volume, and filter sterilized. The PTM salts solution was included at a ratio of 4 ml per liter of initial medium volume after sterilization of the basal salts medium.

[0145] [Table 21]

[0146] Growth period: The growth phase was initiated by inoculating basal salts medium in a 50 L fermenter with a 5% seed culture and continued for approximately 24 hours. Dissolved oxygen (DO) levels were continuously monitored to ensure they did not drop below 40%.

[0147] After 18 hours, a DO spike was observed indicating exhaustion of the carbon source (glycerol). 50% glycerol (with 12 ml of PTM salts per liter of feed) was added to the culture at OD 600 The glycerol feed batch was started by feeding for approximately 6 hours until the .DELTA. reached 200.

[0148] Induction period: Once sufficient biomass was produced, the induction phase was initiated by stopping the glycerol feed and starting the methanol feed. Methanol (supplemented with 12 ml of PTM salts per liter of feed) was fed at a rate of 0.5 g to 3 g per liter of initial fermentation volume. The DO was maintained at 40% and the methanol feed was adjusted accordingly.

[0149] The induction of the FTase gene was monitored periodically by analyzing the culture supernatant by enzyme activity assay. OD 600 The induction phase was continued for approximately 100 hours until the .DELTA. reached 600 and the wet biomass reached approximately 560 grams per liter of culture broth.

[0150] Fermentation was stopped after approximately 130 hours and enzyme activity in the fermenter broth was determined by DNS method (Miller, 1959) at the end of fermentation. One unit is defined as the amount of enzyme required to release 1 micromole of reducing sugar (glucose equivalent) from a 10% sucrose solution in 100 mM citrate buffer, pH 5.5, 55°C. The total amount of recombinant FTase in the culture broth was estimated by Bradford assay.

[0151] Fermentation conditions: The fermentation parameters considered were as listed in Table 12. These essential parameters were monitored during the fermentation process.

[0152] [Table 22]

[0153] Example 5: Cell harvesting and purification Recovery of the enzyme was carried out by continuous centrifugation at 8000 RPM. The clear supernatant obtained after centrifugation was subjected to microfiltration using a 0.1 micron cut-off spiral wound TFF membrane. The filtrate was further subjected to ultrafiltration and diafiltration using a 10 kDa cut-off spiral wound TFF membrane to concentrate sufficiently to reach the desired activity. The enzyme was formulated by including 35-50% glycerol and food grade preservatives in the final preparation. The final purity of the enzyme was observed to be 85% as determined by SDS-PAGE analysis.

[0154] SDS-PAGE analysis of samples collected at different time intervals during the fermentation of Pichia pastoris strain expressing recombinant Ftase enzyme was also performed. SDS-PAGE analysis of the purified recombinant Ftase enzyme was also performed.

[0155] Figure 5 shows SDS-PAGE analysis for screening of protein expression in Pichia pastoris recombinant strains harboring integration (a): pPICZαA-V44L; (b): pPICZαA-T155R; (c): pPICZαA-T293W; (d): pPICZαA-R286V; (c): pPICZαA-R199K; (f): pPICZαA-T459R; (g): pPICZαA-F182P.

[0156] Figure 6 shows SDS-PAGE analysis of samples collected at different time intervals during the fermentation trace of various mutant Ftase proteins: (a): pPICZαA-V44L; (b): pPICZαA-T155R; (c): pPICZαA-T293W; (d): pPICZαA-R286V; (c): pPICZαA-R199K; (f): pPICZαA-T459R; (g): pPICZαA-F182P.

[0157] Figure 10 shows SDS-PAGE analysis for screening of protein expression in Pichia pastoris recombinant strains harboring integration (a): pPICZαA-H43Y; (b): pPICZαA-H43L; (c): pPICZαA-Q327N; (d): pPICZαA-V343F.

[0158] The Ftase concentration was found to be about 2.4 grams / L. In most of the batches, the concentration was between 2 and 5 grams / L. The purity of the recombinant Ftase was observed to be about 85%.

[0159] Example 6: Estimation of Ftase activity A test was carried out to estimate the activity of Ftase. For the estimation test, the amount of reducing sugar generated due to the action of Ftase enzyme was calculated using the DNS (3,5 dinitrosalicylic acid) method (GL Miller, “Use of dinitrosalicylic acid reagent for determination of reducing sugar”, Anal. Chem., 1959, 31, 426-428).

[0160] To perform the enzyme activity assay, 10% sucrose (dissolved in 100 mM citrate buffer) was used as a substrate. Ftase was recovered from the fermentation broth and processed via ultrafiltration. The ultrafiltered sample was then diluted 25,000-fold by serial dilution in 100 mM citrate buffer and used. The reaction volume was 2.5 mL. The pH was maintained at 5.5 and the reaction was allowed to continue for 15 minutes.

[0161] After incubation, 3 mL of DNS (3,5 dinitrosalicylic acid) was added to each reaction mixture, boiled for 10 minutes, cooled, and the absorbance at 540 nm was read spectrophotometrically. The OD of glucose at different concentrations was measured as shown in Table 13. Then, based on the absorbance measurements after the reaction, the enzyme activity was calculated as shown in Table 14.

[0162] [Table 23]

[0163] [Table 24]

[0164] The FTase activity of the different clones was estimated 96 hours after methanol induction. The supernatant of each clone was subjected to TCA precipitation. The TCA-prepped samples were then tested for FTase activity (by DNS method) according to the above reference. Multiple clones of each construct were tested for FTase activity. Data from a representative clone are presented in Table 15. The FTase activity of the wild-type molecule, found to be 290 units / ml, was considered as the experimental control.

[0165] The FTase activity of mutant variants, including but not limited to N32R, H43V, V125F, V127A, P131Y, T155R, F182P, F182R, F182A, F182D, F182V, F182T, R286V, T293F, T293H, T293L, T293S, T293W, H43Y, H43L, Q327N, Q327L and V343F, was surprisingly found to be good.

[0166] [Table 25]

[0167] [Table 26]

[0168] Example 7: Production of fructooligosaccharides (FOS) from sucrose and recombinant FTase enzyme A study was performed to understand the enzyme's ability in forming fructooligosaccharides. A 100 mL solution of 90% (w / v) sucrose was prepared in 150 mM sodium citrate buffer pH 5.5. To this was added 96.7 μL of FTase enzyme with an activity of 51692 units / ml (equivalent to a total of 5000 units of enzyme).

[0169] The reactions were set up in 250 mL conical flasks and incubated at 65° C. and 220 rpm. Samples were taken at regular time intervals and analyzed on thin layer chromatography (TLC) plates.

[0170] Glucose, sucrose, fructose and FOS (including kestose, nystose and fructofuranosyl nystose) were used as standards for thin layer chromatography analysis. The mobile phase used was n-butanol:glacial acetic acid:water (4:2:2 v / v) and the developing / staining solution used was urea phosphate.

[0171] FIG. 7 shows the TLC analysis performed on the production of fructooligosaccharides (FOS) from sucrose and recombinant FTase enzyme.

[0172] The samples were further subjected to high performance liquid chromatography (HPLC) for quantitative estimation of fructooligosaccharide production. HPLC analysis was performed using an amine column (Zorbax NH2 column, Agilent Technologies) with 4.6 (ID) x 150 mm (length) and 5 μm (particle size). Standard solutions of glucose, fructose, kestose, nystose, fructofuranosylnystose and sucrose with different concentrations were run for standard curve generation.

[0173] FIG. 8 shows the HPLC analysis chromatograms of the FOS samples.

[0174] Example 8: Characterization of recombinant FTase from Aspergillus sp. The recovered FTases from Aspergillus sp. selected from, but not limited to, fructosyltransferase from Aspergillus japonicus and β-fructofuranosidase from Aspergillus niger were characterized to identify bioactive fragments. As illustrated in Table 3 above, the following bioactive fragments were found to be conserved and responsible for catalytic activity:

[0175] A similar approach as above was used to generate mutants of FTase from Aspergillus japonicus. The protein sequences of FTase in A. niger and A. japonicus differ only at four loci out of 654 loci, namely 44, 199, 459 and 654, as illustrated in Figure 12. In terms of activity, both enzymes (from genes ft and fopA) were found to be equivalent to each other.

[0176] advantage: 1. The enzyme exhibits high purity after filtration, which eliminates the need for costly chromatography procedures. 2. Enzymes can be used to obtain high yields of fructooligosaccharides.

Claims

1. A modified polypeptide that is an FTase of Aspergillus sp., comprising a mutation selected from, but not limited to, a single point mutation or multiple point mutations or deletion mutations or a combination thereof.

2. The point mutations include, but are not limited to, N32R, R166Y, H240F, H43Q, N32K, T155W, R286I, V382L, Q406R, A371E, T293Q, F118Y, H43Y, R166N, F259W, H43F, H43A, T155Y, L322Y, F568Y, T293F, A371M, T293V, L78R, H43V, F182P, R286V, H43S, H43N, T155M, I324Q, Q586K, T293H, E405W, T293Y, L78W, H43L, F182R, V343F, P131R , H43K, R166L, V343Q, Q586Y, T293I, N290L, A188H, N290K, H43R, F182A, V34 3L, T155L, V127I, R166Q, V343K, Q586V, T293K, N290M, A188K, N290Q, H43T, F 182D, 381R, T155V, V127M, H180Y, V343Y, Q586W, T293L, N290R, D191A, Q327 C, H43M, F182V, A381L, R166K, P131H, H180R, V343I, A188R, T293R, Q327A, D1 91N, Q327I, H43I, F182T, L440R, R166H, P131F, F182M, A381V, D191K, T293S , Q327D, D191W, Q327K, V125F, F182L, Q586R, F182E, P131Q, F182H, A381K, D 191R, T293W, Q327E, A371L, Q327V, V127A, F182W, N32Q, A381I, T132L, F182 S, A381P, Q327G, A188F, Q327F, A371V, Q406K, P131Y, F182N, N32V, Q586F, T1 32M, Y232W, A381Q, Q327H, A188Q, Q327R, E405F, Q406M, P131W, F182K, H43W , N32D, T132V, H240R, A381T, Q327L, D191E, Q406L, E405G, S329N, T155R, F18 2Q, H43E, N32I, T132I, H240K, A381Y, Q327M, D191F, T293M, E405L, S329T, T 155K, R196K, H43D, N32Y, T155I, F259Y, V382I, Q327N, D191Q, T293N, E405N,2. The modified polypeptide of claim 1, wherein the modified polypeptide is selected from Y404W, V44L, K199R, R459T, N654K, L44V, R199K, T459R, and K654N.

3. 2. The modified polypeptide of claim 1, wherein the deletion mutation is selected from, but not limited to, 32-654 aa, 32-194 aa, 1-194 aa.

4. 2. The modified polypeptide of claim 1, wherein the polypeptide sequence is selected from, but not limited to, SEQ ID NOs: 9-218.

5. The modified polypeptide of claim 4, wherein the polypeptide sequence is selected from SEQ ID NOs: 9-66.

6. A polynucleotide comprising a nucleic acid molecule encoding the modified polypeptide of claim 1.

7. 2. The polypeptide of claim 1, wherein the amino acid sequence or nucleotide sequence is further fused to a signal peptide selected from the group including FAK, FAKS, AT, AA, GA, IN, IV, KP, LZ and SA or variants thereof.

8. a. FAK comprises the amino acid sequence of SEQ ID NO: 219 or a variant thereof; b. FAKS comprises the amino acid sequence of SEQ ID NO: 229 or a variant thereof; c. AT comprises the amino acid sequence of SEQ ID NO: 220 or a variant thereof; d. AA comprises the amino acid sequence of SEQ ID NO: 221 or a variant thereof; e. GA comprises the amino acid sequence of SEQ ID NO: 222 or a variant thereof; f. IN comprises the amino acid sequence of SEQ ID NO: 223 or a variant thereof; g. IV comprises the amino acid sequence of SEQ ID NO: 224 or a variant thereof; h. KP comprises the amino acid sequence of SEQ ID NO: 225 or a variant thereof; i. LZ comprises the amino acid sequence of SEQ ID NO: 226 or a variant thereof; and j. SA comprises the amino acid sequence of SEQ ID NO: 227 or a variant thereof; The modified polypeptide of claim 7 , wherein the signal peptide enables extracellular secretion of the polypeptide.

9. An expression vector comprising the nucleic acid molecule of claim 6 operably linked to a promoter.

10. 10. The expression vector of claim 9, wherein the promoter for the FTase gene is a constitutive, inducible promoter selected from the group including AOX1, ADH3, DAS, FLD1, LRA3, THI11, GAP, YPT1, TEF1, GCw14 and PGK1.

11. 10. The expression vector of claim 9, selected from the group comprising pPICZαA, pPICZαB, pPICZαC, pGAPZαA, pGAPZαB, pGAPZαC, pPIC3, pPIC3.5, pPIC3.5K, PAO815, pPIC9, pPIC9K, pHIL-D2 and pHIL-S1 and expression vectors configured for secretion or intracellular expression of FTase.

12. 10. A recombinant host cell comprising the expression vector of claim 9, selected from the group consisting of Escherichia coli, Bacillus subtilis, Pseudomonas putida, Corynebacterium glutamicum, Saccharomyces cerevisiae, Pichia pastoris and Hansenula polymorpha.

13. 13. The recombinant host cell of claim 12, selected from the group comprising Pichia pastoris Mut+, Mut S, Mut, Pichia pastoris KM71H, Pichia pastoris KM71, Pichia pastoris SMD1168H, Pichia pastoris SMD1168, Pichia pastoris X33, Pichia pastoris GS115 or any other Pichia pastoris host strain.

14. 2. A method for producing a recombinant host cell capable of expressing the modified FTase of Aspergillus sp. according to claim 1, comprising the steps of: a. synthesizing a modified nucleic acid molecule according to claim 6; b. constructing a vector carrying the modified nucleic acid molecule; c. transforming a host cell with the vector of step (b) to obtain a recombinant host cell; The method includes:

15. 15. The method of claim 14, wherein the modified nucleic acid molecule comprises at least one or more point mutations as described in claim 2 or deletion mutations as described in claim 3, or a combination thereof.

16. 2. A process for expressing the modified FTase of Aspergillus sp. according to claim 1, comprising: a. Cultivating a recombinant host cell capable of expressing an Aspergillus sp. FTase in a suitable fermentation medium to obtain a fermentation broth; b. recovering a supernatant from the fermentation broth, the supernatant containing the recombinant FTase; c. Purifying the recombinant FTase; A process including.

17. 17. The process of claim 16, wherein the fermentation medium is a basal salts medium.

18. 17. The process of claim 16, wherein the pH of the fermentation broth is maintained in the range of 4.0 to 7.5 and the temperature of the fermentation broth is maintained in the range of 15°C to 45°C.

19. 1. A process for identifying amino acid mutations spanning an FTase protein including an active site, comprising the steps of: a. simulating the apo structure of the FTase enzyme using bioinformatics tools; b. Clustering the trajectories based on the variation of root mean square deviation (RMSD) to identify unique conformations; c. Identifying the unique conformation that the FTase enzyme adopted during the course of the simulation residues for mutation; d. analyzing the identified unique conformations of step (c) for pairwise interactions of each amino acid with other amino acids; e. Quantifying the pairwise interactions of the amino acids as index interaction strengths by providing appropriate weights for van der Waals and hydrogen bonds between pairs of residues; f. generating 19 mutations of each amino acid found to have the largest standard deviation of said interaction strengths through said course of said simulation; g. Identifying and selecting stabilizing mutations with similar or better stability according to -ΔΔG values; The process includes:

20. 20. The process according to claim 19, wherein the protein is selected from Aspergillus sp., preferably Aspergillus niger, Aspergillus japonicus.

Citation Information

Patent Citations

  • β-fructofuranosidase and its gene, method for isolating the β-fructofuranosidase gene, β-fructofuranosidase production system, and β-fructofuranosidase mutants.

    JP3628336B2

  • Method for preparing fructooligosaccharides

    KR102049573B1

  • A modified beta-fructofuranosidase for fructooligosaccharide production

    US20170298332A1

  • β-FRUCTOFURANOSIDASE MUTANT

    WO2005085447A1

  • Nucleic acids, vectors, host cells and methods for production of beta-fructofuranosidase from aspergillus niger

    WO2021106016A1